Insmed reported $544.76M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Cytokinetics USD 255.27M 125.43M Jun/2026
DBV Technologies USD 174.9M 54.3M Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Insmed USD 544.76M 37.42M Jun/2026
Novartis USD 6.88B 2.68B Mar/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026